Zheng Quan Zhi Xing·2025-07-15 09:33Core Viewpoint - The company is progressing with the establishment of the Suzhou Angel Fund, which has undergone a capital reduction of RMB 76 million, reducing the total subscribed capital from RMB 176 million to RMB 100 million, while maintaining the ownership proportions of the partners involved [1][2][3]. Fundraising Situation - The Suzhou Angel Fund was established in January 2022 with a total subscribed capital of RMB 176 million, of which RMB 94.25 million has been paid in as of the announcement date [3][6]. - The fund's partners include the company through its subsidiary Ningbo Fuying, which has subscribed RMB 110 million (with RMB 61.25 million paid in), holding 62.50% of the fund [1][3]. Transaction Overview - The capital reduction was agreed upon by all partners due to the approaching end of the fund's investment period and the need for funds for investment plans, resulting in a total reduction of RMB 76 million [2][4]. - After the reduction, the subscribed capital of the Suzhou Angel Fund will be RMB 100 million, with the ownership proportions remaining unchanged [2][3]. Fund Basic Information - The Suzhou Angel Fund focuses on early-stage investments in the biopharmaceutical and healthcare sectors [6][7]. - As of the announcement date, the fund's total assets were RMB 99.14 million, with net assets attributable to partners at RMB 99.05 million [7]. Related Party Transactions - The capital reduction constitutes a related party transaction as one of the partners, Xing Sheng Fu Ying, is a subsidiary of the company's controlling shareholder, Fosun High Technology [2][4]. - The transaction has been approved by the company's board of directors and does not require shareholder approval [5][10].